July 23, 2012 — The U.S. Food and Drug Administration (FDA) granted Ferring Pharmaceuticals Inc. approval to market Prepopik (sodium picosulfate, magnesium oxide and anhydrous citric acid) for oral solution indicated for cleansing of the colon as a preparation for colonoscopy in adults. Prepopik is a low-volume, orange-flavored, dual acting, stimulant and osmotic laxative.

The FDA approval is based on data from two pivotal Phase III non-inferiority studies in which Prepopik was compared to 2L PEG+E plus 2x 5-mg bisacodyl tablets. In both studies, Prepopik achieved the primary endpoint (successful colon cleansing based on the Aronchick scale), demonstrating non-inferiority to the comparator (Study 1: 84.2% v. 74.4%; Study 2: 83.0% v. 79.7%). Additionally, Prepopik demonstrated statistical superiority in cleansing of the colon versus the comparator.

The most common (>1%) adverse reactions in Study 1 possibly or probably related to Prepopik (n=305) versus the study comparator (n=298) were nausea (2.6% v. 3.7%), headache (1.6% v. 1.7%) and vomiting (1.0% v. 3.4%). The most common (>1%) adverse reactions in Study 2 possibly or probably related to Prepopik (n=296) versus the comparator (n=302) were nausea (3.0% v. 4.3%), headache (2.7% v. 1.7%) and vomiting (1.4% v. 2.0%).

Once commercially available, Prepopik will be the lowest volume active ingredient colon preparation available – with 10 ounces of prep solution.

Colon cancer is the third most common cancer and second leading cause of cancer death in the United States. Colonoscopies have been shown to help reduce the incidence of colon cancer and deaths associated with the disease. Complete visualization of the bowel is needed to conduct a thorough colonoscopy to identify precancerous lesions and diagnose other gastrointestinal disorders. Aversion to bowel prep solutions, including the substantial liquid volume, has been recognized as a key barrier to completion of essential colonoscopy prep regimens.

"Successful bowel prep is critical for gastroenterologists to clearly see any polyps or abnormalities, yet the sheer volume of prep solutions can prevent patients from adequately completing their prep regimens, leading to suboptimal visualization of the colon," said Douglas K. Rex, director of endoscopy at Indiana University Hospital and professor in the division of gastroenterology and hepatology at University of Indiana School of Medicine.

Prepopik is approved with two dosing options. Preferably, it can be given as the American College of Gastroenterology (ACG)-recommended split-dose taken in the evening before and on the morning of the procedure. Recommended by the ACG as the optimal way to prepare for colonoscopy, split-dosing has been shown to improve cleansing quality given its greater proximity to procedure time, and appears to have higher compliance due to better tolerability of the liquid volume. Day-before dosing is an alternative regimen for patients for whom split-dosing is inappropriate, accounting for colonoscopy scheduling, distance traveled and other personal circumstances.

"Ferring has a strong global GI presence and with this approval, we are very pleased to introduce Prepopik as our first gastroenterology product in the United States," said Aaron Graff, president and chief operating officer, Ferring Pharmaceuticals Inc. "Colonoscopy rates are lower than the target set forth by public health initiatives to detect and prevent colorectal cancer. Adults who have avoided getting screened may benefit from this effective regimen with the lowest active ingredient volume of any FDA-approved bowel prep."

For more information: www.prepopik.com


Related Content

News | ACR

February 6, 2024 — An update to the CT Colonography Reporting and Data System (C-RADS) has been published Jan. 30 in the ...

Time February 06, 2024
arrow
News | Colonoscopy Systems

A team of Johns Hopkins data researchers is studying the economic and safety implications associated with the devices used to perform colonoscopies as a disposable version inches closer to widespread availability.

Time August 26, 2019
arrow
News | Colonoscopy Systems

A new study finds that trends in colonoscopy rates did not fully align with the increase in colorectal cancer (CRC) in younger adults, adding to evidence that the rise in early onset CRC is not solely a result of more detection. The study is published early online in the Journal of Medical Screening.

Time August 06, 2019
arrow
News | Colonoscopy Systems

Check-Cap Ltd. has initiated its U.S. pilot study of the C-Scan system for prevention of colorectal cancer through detection of precancerous polyps, following Institutional Review Board (IRB) approval and full Investigational Device Exemption (IDE) application approval by the U.S. Food and Drug Administration (FDA). The first patients have ingested C-Scan, a preparation-free capsule, at the New York University School of Medicine.

Time April 15, 2019
arrow
News | Colonoscopy Systems

https://www.congress.gov/bill/115th-congress/house-bill/1298?q=%7B%22se… cancer care advocacy groups and medical societies are calling on Congress to pass the CT Colonography Screening for Colorectal Cancer Act (S.3465/HR 1298). The bipartisan bill introduced in the U.S. Senate September 19 would provide Medicare coverage for screening computed tomography colonography (CTC), commonly known as virtual colonoscopy.

Time September 27, 2018
arrow
News | Colonoscopy Systems

Check-Cap Ltd. announced the interim results for its post-CE approval study of the C-Scan system Version 3, an ingestible, capsule-based device for preparation-free colorectal cancer (CRC) screening. The company said data from the multicenter clinical investigation showed promising results for detecting patients with polyps in an un-prepped colon.

Time September 04, 2018
arrow
News | Colonoscopy Systems

An updated American Cancer Society guideline says colorectal cancer screening should begin at age 45 for people at average risk. The recommendation is based in part on data showing rates of colorectal cancer are increasing in young and middle-aged populations.

Time May 30, 2018
arrow
News | Colonoscopy Systems

February 8, 2018 – The U.S. Food and Drug Administration (FDA) announced on February 7, 2018, that Pentax Medical’s ...

Time February 08, 2018
arrow
News | Colonoscopy Systems

August 31, 2017 — A fast, simple blood test for ulcerative colitis using infrared spectroscopy could provide a cheaper ...

Time August 31, 2017
arrow
News | Colonoscopy Systems

People with insurance policies that cover computed tomography (CT) colonography for colorectal cancer screening are almost 50 percent more likely to get screened than those whose policies don’t cover the procedure, according to a new study appearing online in the journal Radiology.

Time July 12, 2017
arrow
Subscribe Now